Clinical cure (also known as functional cure) of chronic hepatitis B (chronic hepatitis B), i.e., completion of a limited course of treatment with persistently undetectable serum HBsAg (hepatitis B surface antigen) and HBVDNA (hepatitis B viral load), HBeAg turn-over with or without the appearance of surface antibodies, remission of hepatic inflammation and improvement of histopathology, and a significant reduction in the incidence of cirrhosis and hepatocellular carcinoma, is the pursuit of the The ultimate goal of hepatitis B. 1.What kind of people can achieve clinical functional cure? Patients with chronic hepatitis B treated with antiviral drugs, with HBsAg quantification <3000IU/ml, and with hepatitis B viral load not detected, are strongly recommended to use interferon in combination with antiviral drugs to achieve functional cure. 2.How long is the course of clinical functional cure? Clinical functional cure is normally evaluated at 12 weeks, 24 weeks, 48 weeks and 96 weeks. In the initial treatment, the lower the surface antigen titer, the higher the chance of achieving clinical cure. , Patients with baseline HBeAg-negative HBsAg and HBsAg <1500 IU/ml had a higher rate of HBsAg conversion at 48 weeks of treatment (22.2%-26.5%), and patients with HBsAg ≥1500 IU/ml had a lower rate of HBsAg conversion (1.6%-3.8%). In addition, patients with HBsAg <200IU/ml at week 12 or 24 of treatment were most likely to achieve HBsAg conversion (48.9%-77.8%). Moreover, many studies have confirmed that chronic hepatitis B can significantly reduce the incidence of hepatocellular carcinoma after interferon treatment throughout the disease cycle, even if clinical functional cure is not achieved. Monitoring after clinical cure After HBsAg (surface antigen) becomes negative, it is still necessary to monitor reactivation of chronic hepatitis B, hepatocellular carcinoma and other hepatic events for a long time. It is recommended to follow up every 3 months in the first year and every 6 months in the second year after the end of treatment, and thereafter every year if HBsAg (surface) remains negative. If relapse occurs, retreatment may be considered after comprehensive evaluation.